Ethical Aspects and Implications of Commercialization of Renal Transplantation: A Global Perspective

End-stage renal disease affects approximately 4.9 million individuals globally, with kidney transplantation providing optimal treatment outcomes. However, organ scarcity has led to commercial transplantation practices that raise significant ethical concerns. A comprehensive literature review using PubMed, EMBASE, and Cochrane databases (2010–2024), focusing on clinical outcomes, ethical frameworks, and regulatory policies regarding commercial transplantation, was conducted. Commercial transplantation accounts for 5%–10% of kidney transplants performed annually worldwide. Clinical outcomes demonstrate consistently inferior results compared to altruistic transplant systems, with higher perioperative complications (40%–65% vs. 10%–15%), increased acute rejection rates (30%–50% vs. 10%–20%), and reduced 5-year graft survival (60%–75% vs. 85%–90%). Ethical concerns include exploitation of vulnerable population, commodification of human organs, and violation of fundamental bioethical principles. Commercial renal transplantation presents complex ethical challenges requiring a comprehensive policy that address underlying organ shortage while protecting the vulnerable population and maintaining the highest clinical standards.